APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market

TABLE OF CONTENTS

1 INTRODUCTION 22

• 1.1 OBJECTIVES OF THE STUDY 22
• 1.2 MARKET DEFINITION 22
• 1.3 OVERVIEW OF ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 22
• 1.4 LIMITATIONS 24
• 1.5 MARKETS COVERED 24

2 MARKET SEGMENTATION 26

• 2.1 MARKETS COVERED 26
• 2.2 GEOGRAPHICAL SCOPE 27
• 2.3 YEARS CONSIDERED FOR THE STUDY 28
• 2.4 CURRENCY AND PRICING 28
• 2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
• 2.6 MULTIVARIATE MODELLING 32
• 2.7 TYPE LIFELINE CURVE 32
• 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
• 2.9 DBMR MARKET POSITION GRID 34
• 2.10 MARKET END USER COVERAGE GRID 35
• 2.11 VENDOR SHARE ANALYSIS 36
• 2.12 SECONDARY SOURCES 37
• 2.13 ASSUMPTIONS 37

3 EXECUTIVE SUMMARY 38

4 PREMIUM INSIGHTS 41

• 4.1 PESTEL ANALYSIS 42
• 4.2 PORTER'S FIVE FORCES 43
• 4.3 INSURANCE REIMBURSEMENT 44
  • 4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 44
  • 4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 44
  • 4.3.3 ABBOTT CODING GUIDE FOR ECMO 45
  • 4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 45
  • 4.3.5 CERN HEALTH INSURANCE SCHEME 46
  • 4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 46
  • 4.3.7 AMERICAN HOSPITAL ASSOCIATION 47
• 4.4 PIPELINE ANALYSIS 48
• 4.5 PRICING ANALYSIS 50

5 MARKET OVERVIEW 51

• 5.1 DRIVERS 53
  • 5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 53
  • 5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 53
  • 5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 54
  • 5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 54
• 5.2 RESTRAINTS 55
  • 5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 55
  • 5.2.2 HIGH COST OF DEVICES AND TREATMENT 55
• 5.3 OPPORTUNITIES 56
  • 5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 56
  • 5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 56
  • 5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 57
• 5.4 CHALLENGES 58
  • 5.4.1 STRINGENT RULES & REGULATIONS 58
  • 5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 59

6 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 60

• 6.1 OVERVIEW 61
• 6.2 MECHANICAL VENTILATION 64
  • 6.2.1 HIGH-FLOW NASAL O2 65
  • 6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 65
  • 6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 65
  • 6.2.4 PRONE POSITION VENTILATION 65
  • 6.2.5 OTHERS 66
• 6.3 CORTICOSTEROIDS 66
  • 6.3.1 METHYLPREDNISOLONE 67
  • 6.3.2 DEXAMETHASONE 67
  • 6.3.3 OTHERS 67
• 6.4 ANTIVIRAL MEDICATION 68
  • 6.4.1 RIBAVIRIN 69
  • 6.4.2 OSELTAMIVIR 69
  • 6.4.3 OTHERS 69
• 6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 69
• 6.6 TOCILIZUMAB 70
• 6.7 OTHERS 70 

7 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 71

• 7.1 OVERVIEW 72
• 7.2 SEPSIS 75
• 7.3 INHALATION OF HARMFUL SUBSTANCES 75
• 7.4 SEVERE PNEUMONIA 76
• 7.5 OTHERS 76

8 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 77

• 8.1 OVERVIEW 78
• 8.2 PARENTERAL 81
  • 8.2.1 INTRAVENOUS 81
  • 8.2.2 INTRAMUSCULAR 81
• 8.3 ORAL 82
• 8.4 OTHERS 82

9 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 83

• 9.1 OVERVIEW 84
• 9.2 HOSPITALS 87
• 9.3 SPECIALTY CLINICS 87
• 9.4 HOME HEALTHCARE 88
• 9.5 OTHERS 88

10 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 89

• 10.1 OVERVIEW 90
• 10.2 DIRECT TENDER 93
• 10.3 HOSPITAL PHARMACY 93
• 10.4 RETAIL PHARMACY 94
• 10.5 ONLINE PHARMACY 94 

11 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 95

• 11.1 ASIA-PACIFIC 97
  • 11.1.1 JAPAN 103
  • 11.1.2 CHINA 108
  • 11.1.3 INDIA 113
  • 11.1.4 SOUTH KOREA 118
  • 11.1.5 AUSTRALIA 123
  • 11.1.6 SINGAPORE 128
  • 11.1.7 THAILAND 133
  • 11.1.8 MALAYSIA 138
  • 11.1.9 INDONESIA 143
  • 11.1.10 PHILIPPINES 148
  • 11.1.11 REST OF ASIA-PACIFIC 153

12 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 154

• 12.1 COMPANY SHARE ANALYSIS: ASIA - PACIFIC 154

13 SWOT ANALYSIS 155

14 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 156

• 14.1 GILEAD SCIENCES INC. 156
  • 14.1.1 COMPANY SNAPSHOT 156
  • 14.1.2 REVENUE ANALYSIS 157
  • 14.1.3 COMPANY SHARE ANALYSIS 157
  • 14.1.4 PRODUCT PORTFOLIO 158
  • 14.1.5 RECENT DEVELOPMENT 158
• 14.2 TERUMO CORPORATION 159
  • 14.2.1 COMPANY SNAPSHOT 159
  • 14.2.2 REVENUE ANALYSIS 159
  • 14.2.3 COMPANY SHARE ANALYSIS 160
  • 14.2.4 PRODUCT PORTFOLIO 160
  • 14.2.5 RECENT DEVELOPMENT 160
• 14.3 GETINGE 161
  • 14.3.1 COMPANY SNAPSHOT 161
  • 14.3.2 REVENUE ANALYSIS 161
  • 14.3.3 COMPANY SHARE ANALYSIS 162
  • 14.3.4 PRODUCT PORTFOLIO 162
  • 14.3.5 RECENT DEVELOPMENT 162
• 14.4 LIVANOVA PLC 163
  • 14.4.1 COMPANY SNAPSHOT 163
  • 14.4.2 REVENUE ANALYSIS 163
  • 14.4.3 COMPANY SHARE ANALYSIS 164
  • 14.4.4 PRODUCT PORTFOLIO 164
  • 14.4.5 RECENT DEVELOPMENTS 164
• 14.5 MEDTRONIC 165
  • 14.5.1 COMPANY SNAPSHOT 165
  • 14.5.2 REVENUE ANALYSIS 165
  • 14.5.3 COMPANY SHARE ANALYSIS 166
  • 14.5.4 PRODUCT PORTFOLIO 166
  • 14.5.5 RECENT DEVELOPMENTS 166
• 14.6 ARMSTRONG MEDICAL 167
  • 14.6.1 COMPANY SNAPSHOT 167
  • 14.6.2 PRODUCT PORTFOLIO 167
  • 14.6.3 RECENT DEVELOPMENT 167
• 14.7 BESMED HEALTH BUSINESS CORP. 168
  • 14.7.1 COMPANY SNAPSHOT 168
  • 14.7.2 PRODUCT PORTFOLIO 168
  • 14.7.3 RECENT DEVELOPMENTS 169
• 14.8 DRAGERWERK AG & CO. KGAA 170
  • 14.8.1 COMPANY SNAPSHOT 170
  • 14.8.2 REVENUE ANALYSIS 170
  • 14.8.3 PRODUCT PORTFOLIO 171
  • 14.8.4 RECENT DEVELOPMENTS 171
• 14.9 EUROSETS 172
  • 14.9.1 COMPANY SNAPSHOT 172
  • 14.9.2 PRODUCT PORTFOLIO 172
  • 14.9.3 RECENT DEVELOPMENT 172
• 14.10 FISHER & PAYKEL HEALTHCARE LIMITED 173
  • 14.10.1 COMPANY SNAPSHOT 173
  • 14.10.2 REVENUE ANALYSIS 173
  • 14.10.3 PRODUCT PORTFOLIO 174
  • 14.10.4 RECENT DEVELOPMENTS 174
• 14.11 FRESENIUS SE & CO. KGAA. 175
  • 14.11.1 COMPANY SNAPSHOT 175
  • 14.11.2 REVENUE ANALYSIS 175
  • 14.11.3 PRODUCT PORTFOLIO 176
  • 14.11.4 RECENT DEVELOPMENT 176
• 14.12 HAMILTON MEDICAL 177
  • 14.12.1 COMPANY SNAPSHOT 177
  • 14.12.2 PRODUCT PORTFOLIO 177
  • 14.12.3 RECENT DEVELOPMENT 177
• 14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD. 178
  • 14.13.1 COMPANY SNAPSHOT 178
  • 14.13.2 PRODUCT PORTFOLIO 178
  • 14.13.3 RECENT DEVELOPMENT 178
• 14.14 NIPRO 179
  • 14.14.1 COMPANY SNAPSHOT 179
  • 14.14.2 REVENUE ANALYSIS 179
  • 14.14.3 PRODUCT PORTFOLIO 180
  • 14.14.4 RECENT DEVELOPMENT 180
• 14.15 PFIZER INC. 181
  • 14.15.1 COMPANY SNAPSHOT 181
  • 14.15.2 REVENUE ANALYSIS 181
  • 14.15.3 PRODUCT PORTFOLIO 182
  • 14.15.4 RECENT DEVELOPMENT 182
• 14.16 RESMED 183
  • 14.16.1 COMPANY SNAPSHOT 183
  • 14.16.2 REVENUE ANALYSIS 183
  • 14.16.3 PRODUCT PORTFOLIO 184
  • 14.16.4 RECENT DEVELOPMENT 184
• 14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 185
  • 14.17.1 COMPANY SNAPSHOT 185
  • 14.17.2 PRODUCT PORTFOLIO 185
  • 14.17.3 RECENT DEVELOPMENT 185

15 QUESTIONNAIRE 186

16 RELATED REPORTS 189

LIST OF TABLES

• TABLE 1 LIST OF PRICES FOR APPROVED DRUGS FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT 50
• TABLE 2 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 63
• TABLE 3 ASIA - PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 64
• TABLE 4 ASIA - PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 64
• TABLE 5 ASIA - PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 65
• TABLE 6 ASIA - PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 65
• TABLE 7 ASIA - PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
• TABLE 8 ASIA - PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 66
• TABLE 9 ASIA - PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 67
• TABLE 10 ASIA - PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 67
• TABLE 11 ASIA - PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 68
• TABLE 12 ASIA - PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 68
• TABLE 13 ASIA - PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 68
• TABLE 14 ASIA - PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 68
• TABLE 15 ASIA - PACIFIC EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 69
• TABLE 16 ASIA - PACIFIC TOCILIZUMAB IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 70
• TABLE 17 ASIA - PACIFIC OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 70
• TABLE 18 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 74
• TABLE 19 ASIA - PACIFIC SEPSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 75
• TABLE 20 ASIA - PACIFIC INHALATION OF HARMFUL SUBSTANCES IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 75
• TABLE 21 ASIA - PACIFIC SEVERE PNEUMONIA IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
• TABLE 22 ASIA - PACIFIC OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
• TABLE 23 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 80
• TABLE 24 ASIA - PACIFIC PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 81
• TABLE 25 ASIA - PACIFIC PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 81
• TABLE 26 ASIA - PACIFIC ORAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
• TABLE 27 ASIA - PACIFIC OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
• TABLE 28 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 86
• TABLE 29 ASIA - PACIFIC HOSPITALS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 87
• TABLE 30 ASIA - PACIFIC SPECIALTY CLINICS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
• TABLE 31 ASIA - PACIFIC HOME HEALTHCARE IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
• TABLE 32 ASIA - PACIFIC OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
• TABLE 33 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 92
• TABLE 34 ASIA - PACIFIC DIRECT TENDER IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 93
• TABLE 35 ASIA - PACIFIC HOSPITAL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 93
• TABLE 36 ASIA - PACIFIC RETAIL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
• TABLE 37 ASIA - PACIFIC ONLINE PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
• TABLE 38 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 97
• TABLE 39 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 98
• TABLE 40 ASIA-PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 98
• TABLE 41 ASIA-PACIFIC MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 99
• TABLE 42 ASIA-PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 99
• TABLE 43 ASIA-PACIFIC CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 99
• TABLE 44 ASIA-PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 100
• TABLE 45 ASIA-PACIFIC ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 100
• TABLE 46 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 100
• TABLE 47 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 101
• TABLE 48 ASIA-PACIFIC PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 101
• TABLE 49 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 101
• TABLE 50 ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 102
• TABLE 51 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 103
• TABLE 52 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 103
• TABLE 53 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 104
• TABLE 54 JAPAN MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 104
• TABLE 55 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 104
• TABLE 56 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 105
• TABLE 57 JAPAN CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 105
• TABLE 58 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 105
• TABLE 59 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 105
• TABLE 60 JAPAN ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 106
• TABLE 61 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 106
• TABLE 62 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 106
• TABLE 63 JAPAN PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 107
• TABLE 64 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 107
• TABLE 65 JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 107
• TABLE 66 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 108
• TABLE 67 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 108
• TABLE 68 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 109
• TABLE 69 CHINA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 109
• TABLE 70 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 109
• TABLE 71 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 110
• TABLE 72 CHINA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 110
• TABLE 73 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 110
• TABLE 74 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 110
• TABLE 75 CHINA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 111
• TABLE 76 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 111
• TABLE 77 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 111
• TABLE 78 CHINA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 112
• TABLE 79 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 112
• TABLE 80 CHINA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 112
• TABLE 81 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 113
• TABLE 82 INDIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 113
• TABLE 83 INDIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 114
• TABLE 84 INDIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 114
• TABLE 85 INDIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 114
• TABLE 86 INDIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 115
• TABLE 87 INDIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 115
• TABLE 88 INDIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 115
• TABLE 89 INDIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 115
• TABLE 90 INDIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 116
• TABLE 91 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 116
• TABLE 92 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 116
• TABLE 93 INDIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 117
• TABLE 94 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 117
• TABLE 95 INDIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 117
• TABLE 96 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 118
• TABLE 97 SOUTH KOREA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 118
• TABLE 98 SOUTH KOREA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 119
• TABLE 99 SOUTH KOREA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 119
• TABLE 100 SOUTH KOREA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
• TABLE 101 SOUTH KOREA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 120
• TABLE 102 SOUTH KOREA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 120
• TABLE 103 SOUTH KOREA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 120
• TABLE 104 SOUTH KOREA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 120
• TABLE 105 SOUTH KOREA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 121
• TABLE 106 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 121
• TABLE 107 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 121
• TABLE 108 SOUTH KOREA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 122
• TABLE 109 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 122
• TABLE 110 SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 122
• TABLE 111 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 123
• TABLE 112 AUSTRALIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 123
• TABLE 113 AUSTRALIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 124
• TABLE 114 AUSTRALIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 124
• TABLE 115 AUSTRALIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 124
• TABLE 116 AUSTRALIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 125
• TABLE 117 AUSTRALIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 125
• TABLE 118 AUSTRALIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 125
• TABLE 119 AUSTRALIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 125
• TABLE 120 AUSTRALIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 126
• TABLE 121 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 126
• TABLE 122 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 126
• TABLE 123 AUSTRALIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 127
• TABLE 124 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 127
• TABLE 125 AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 127
• TABLE 126 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 128
• TABLE 127 SINGAPORE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 128
• TABLE 128 SINGAPORE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 129
• TABLE 129 SINGAPORE MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 129
• TABLE 130 SINGAPORE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 129
• TABLE 131 SINGAPORE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 130
• TABLE 132 SINGAPORE CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 130
• TABLE 133 SINGAPORE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 130
• TABLE 134 SINGAPORE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 130
• TABLE 135 SINGAPORE ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 131
• TABLE 136 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 131
• TABLE 137 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 131
• TABLE 138 SINGAPORE PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 132
• TABLE 139 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 132
• TABLE 140 SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 132
• TABLE 141 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
• TABLE 142 THAILAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
• TABLE 143 THAILAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 134
• TABLE 144 THAILAND MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 134
• TABLE 145 THAILAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 134
• TABLE 146 THAILAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 135
• TABLE 147 THAILAND CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 135
• TABLE 148 THAILAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 135
• TABLE 149 THAILAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 135
• TABLE 150 THAILAND ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 136
• TABLE 151 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 136
• TABLE 152 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 136
• TABLE 153 THAILAND PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 137
• TABLE 154 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 137
• TABLE 155 THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 137
• TABLE 156 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 138
• TABLE 157 MALAYSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 138
• TABLE 158 MALAYSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 139
• TABLE 159 MALAYSIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 139
• TABLE 160 MALAYSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 139
• TABLE 161 MALAYSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 140
• TABLE 162 MALAYSIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 140
• TABLE 163 MALAYSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 140
• TABLE 164 MALAYSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 140
• TABLE 165 MALAYSIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 141
• TABLE 166 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 141
• TABLE 167 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 141
• TABLE 168 MALAYSIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 142
• TABLE 169 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 142
• TABLE 170 MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 142
• TABLE 171 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
• TABLE 172 INDONESIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
• TABLE 173 INDONESIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 144
• TABLE 174 INDONESIA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 144
• TABLE 175 INDONESIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 144
• TABLE 176 INDONESIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 145
• TABLE 177 INDONESIA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 145
• TABLE 178 INDONESIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 145
• TABLE 179 INDONESIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 145
• TABLE 180 INDONESIA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 146
• TABLE 181 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 146
• TABLE 182 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 146
• TABLE 183 INDONESIA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 147
• TABLE 184 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 147
• TABLE 185 INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 147
• TABLE 186 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 148
• TABLE 187 PHILIPPINES MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 148
• TABLE 188 PHILIPPINES MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 149
• TABLE 189 PHILIPPINES MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 149
• TABLE 190 PHILIPPINES CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 149
• TABLE 191 PHILIPPINES CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 150
• TABLE 192 PHILIPPINES CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 150
• TABLE 193 PHILIPPINES ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 150
• TABLE 194 PHILIPPINES ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (VOLUME) 150
• TABLE 195 PHILIPPINES ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (ASP) 151
• TABLE 196 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE, 2021-2030 (USD THOUSAND) 151
• TABLE 197 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 151
• TABLE 198 PHILIPPINES PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 152
• TABLE 199 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 152
• TABLE 200 PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 152
• TABLE 201 REST OF ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 153

LIST OF FIGURES

• FIGURE 1 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION 26
• FIGURE 2 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DATA TRIANGULATION 29
• FIGURE 3 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DROC ANALYSIS 30
• FIGURE 4 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: ASIA - PACIFIC VS REGIONAL MARKET ANALYSIS 31
• FIGURE 5 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY RESEARCH ANALYSIS 31
• FIGURE 6 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: INTERVIEW DEMOGRAPHICS 33
• FIGURE 7 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DBMR MARKET POSITION GRID 34
• FIGURE 8 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: MARKET END USER COVERAGE GRID 35
• FIGURE 9 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: VENDOR SHARE ANALYSIS 36
• FIGURE 10 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION 40
• FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY ARE EXPECTED TO DRIVE THE ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2030 41
• FIGURE 12 MECHANICAL VENTILATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2023 & 2030 41
• FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA - PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 52
• FIGURE 14 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, 2022 61
• FIGURE 15 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 62
• FIGURE 16 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, CAGR (2023-2030) 62
• FIGURE 17 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY TYPE, LIFELINE CURVE 63
• FIGURE 18 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, 2022 72
• FIGURE 19 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, 2023-2030 (USD THOUSAND) 73
• FIGURE 20 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, CAGR (2023-2030) 73
• FIGURE 21 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY CAUSE, LIFELINE CURVE 74
• FIGURE 22 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 78
• FIGURE 23 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 79
• FIGURE 24 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 79
• FIGURE 25 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 80
• FIGURE 26 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, 2022 84
• FIGURE 27 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 85
• FIGURE 28 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, CAGR (2023-2030) 85
• FIGURE 29 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY END USER, LIFELINE CURVE 86
• FIGURE 30 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 90
• FIGURE 31 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 91
• FIGURE 32 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 91
• FIGURE 33 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 92
• FIGURE 34 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: SNAPSHOT (2022) 96
• FIGURE 35 ASIA - PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET: COMPANY SHARE 2022 (%) 154